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Abstract
Objective—To describe trends and identify factors associated with choice of pharmacotherapy
for gestational diabetes (GDM) from 2000–2011 using a healthcare claims database.
Methods—This was a retrospective cohort study of a large nationwide population of
commercially insured women with GDM and pharmacy claims for glyburide or insulin prior to
delivery, 2000–2011. We excluded women younger than 15 years or older than 50 years, those
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with prior type 2 diabetes, or those who had multiple gestations. We estimated trends over time in
the use of glyburide compared with insulin and prevalence ratios (PR) and 95% confidence
intervals (CI) for the association between covariates of interest and treatment with glyburide
compared with insulin.
Results—We identified 10,778 women with GDM treated with glyburide (n=5,873) or insulin
(n=4,905). From 2000–2011, glyburide use increased from 7.4% to 64.5%, becoming the more
common treatment in 2007. Women less likely to be treated with glyburide were those with
metabolic syndrome (PR=0.71, 95%CI: 0.50– 0.99), hyperandrogenism (PR=0.77, 95%CI: 0.62–
0.97), polycystic ovarian syndrome (PR=0.88, 95%CI: 0.78–0.99), hypothyroidism (PR=0.89,
95%CI: 0.83–0.96) or undergoing infertility treatment (PR=0.93, 95%CI: 0.86–1.02). The
probability of receiving glyburide decreased by 5% for every 10-year increase in maternal age
(PR=0.95, 95%CI: 0.91–0.99). Among women prescribed with glyburide, 7.8% switched or
augmented to a different drug class compared with 1.1% of insulin initiators.
Conclusion—Glyburide has replaced insulin as the more common pharmacotherapy for GDM
over the last decade among those privately insured. Given its rapid uptake and the potential
implications of suboptimal glucose control on maternal and neonatal health, robust evaluation of
glyburide’s relative effectiveness is warranted to inform treatment decisions for women with
gestational diabetes.
INTRODUCTION
The prevalence of gestational diabetes mellitus (GDM) in the United States more than
doubled from 1.5% in 1989–1990 to 4.2% 2001–2004. Between 7–35% of diagnosed
women will require pharmacological treatment during pregnancy (1). The only Food and
Drug Administration approved medication for the treatment of GDM is insulin (2) although
glyburide (an oral agent), is also used (3).
Glyburide is a second generation sulfonylurea, thought to be effective for the treatment of
GDM (4). Glyburide is believed to be safe based on results from animal and in-vitro
placental studies showing minimal transfer (5, 6), although recent studies in humans have
shown fetal transfer (7). Its ease of use and low cost are advantages compared to insulin
which is administered by injection and entails higher costs (8).
In 2000, Langer et al. conducted the first randomized controlled trial (RCT) comparing
glyburide to insulin in 404 women with GDM (9). Since then, two more RCTs (10, 11),
three observational studies (12–14) and two meta-analyses (15, 16) have compared the
efficacy or effectiveness of the two drugs. It is unknown how evidence from these studies
has affected choice of medication in routine practice and which factors influence the
prescription of glyburide compared with insulin. There are no current estimates of the
dissemination of glyburide use during pregnancy, in the US population.
Our objective was to characterize pharmacological treatment of women with GDM by
describing trends in the use of glyburide compared with insulin over the last decade, and
identifying predictors of initial choice of pharmacotherapy.
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We conducted a retrospective cohort study of women with gestational diabetes identified in
Truven Health’s MarketScan Commercial Claims and Encounters database from 2000–
2011. This database is the largest collection of claims from patients with employer-
sponsored health insurance in the United States (17). Data from individual patients are
integrated from all providers of care over time, for as long as the patient is enrolled in the
employer’s health plan. Truven Health Analytics reviews all claims and enrollment data to
ensure completeness, accuracy, and reliability.
The database has information from over 100 payers of private health insurance for
employees and their dependents, covering more than 25 million lives annually. It contains
details of enrollment, demographics (age, sex, geographic region), inpatient/outpatient
services, and outpatient pharmacy data. These data include information about diagnoses
(ICD-9-CM diagnosis codes) and procedures (CPT-4 and ICD-9-CM procedure codes), in
the outpatient and inpatient settings reported on administrative claims. Data on prescription
medications (National Drug Codes) filled through outpatient pharmacies are also reported
using insurance claims. Each enrolled individual is assigned a unique, encrypted
identification number making it possible to link records and obtain nearly comprehensive
record of encounters with the health care system.
We identified women who had claims for delivery of a live born infant through the use of
ICD-9 diagnosis, procedure and CPT-4 codes (see the Appendix online at http://
links.lww.com/xxx). Because multiple claims can be generated during delivery care, we
grouped those occurring consecutively and defined delivery date as the date of the earliest
claim. Women were required to be continuously enrolled during the year prior to and at least
three months after the delivery date (Figure 1A).
For each delivery, we identified women who had a claim with a diagnosis code for GDM
(ICD-9-CM 648.8–648.83) in the year prior to delivery date. If two deliveries occurred
within a 12-month period, GDM diagnosis codes for the second pregnancy were assessed in
the period beginning 6 weeks after the delivery date of the first pregnancy. The six week
period was used to avoid capturing GDM diagnosis codes which might occur postpartum
from the first pregnancy (Figure 1B). We excluded women 1) with diagnosis codes for type
1 or 2 diabetes; 2) younger than 15 years or older than 50 years old; and 3) with diagnosis or
procedure codes for pregnancy with multiple gestations. Our cohort was restricted to the
first eligible GDM pregnancy for a given woman.
We identified women in our cohort with a pharmacy claim for insulin or glyburide using
NDC codes. Women were classified as insulin or glyburide initiators based on the drug class
of their first claim; the date on this claim was defined as initiation of pharmacotherapy
(index date). We excluded those initiating pharmacological treatment after delivery or who
had an index date occurring earlier than 150 days before delivery (suggestive of
management for pre-pregnancy type 2 diabetes). We also identified treatment changes
occurring after the index date but prior to delivery. Change in pharmacotherapy was defined
as any claim occurring after the index date for a drug class different to that prescribed at
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initiation. We also identified a group of women with GDM who were not treated
pharmacologically within 150 days of delivery. We excluded from this analysis women
whose index prescription was for thiazolidindiones (n=181) or acarbose (n=27).
We identified characteristics that might influence the choice of initial therapy (insulin or
glyburide) for GDM. All characteristics were defined through the use of ICD-9-CM
diagnosis or CPT-4 codes, and assessed before the index date. Comorbidities of interest
were: infertility diagnosis (ICD-9-CM V26.8, V26.81 CPT-4 89252, 89268, 89281, 58310,
58311, 58321–23, 58970–76, 89250–57, 89268, 89272, 89280–81, 89290–91, 89352–54) or
treatment (at least 1 claim for clomiphene, urofollitropin, follitropin, menotropin, ganirelix,
cetrorelix); obesity (ICD-9-CM 278.0X, 649.1X, V77.8, V85.3x, V85.4); hypothyroidism
(ICD-9-CM 244.X); hyperandrogenism (defined as an ICD-9-CM code for alopecia
[704.0X], hirsutism [704.1] or acne [706.0, 706.1]); metabolic syndrome (ICD-9-CM
277.7); and polycystic ovarian syndrome (ICD-9-CM 256.4). Because metformin is used off
label for infertility or to reduce risk of miscarriage we identified use of metformin early in
pregnancy (>150 days prior to delivery) and used this as a covariate in the analyses.
Trends in the use of glyburide compared with insulin between years 2000–2010 were
estimated by calculating the proportion of women who initiated glyburide, using as
denominator the total number of women treated with medication in a given year.
Multivariable log-linear regression was used to estimate average annual percent change and
95% confidence intervals (CI) in the use of glyburide for the overall period and within
intervals of interest (18). Binomial regression was used to adjust for covariates of interest
using fractional polynomials to flexibly model the association between age and choice of
initial therapy (19). We estimated prevalence ratios (PR) and 95% CI for the association
between baseline characteristics (age, region, comorbidities, calendar time) and treatment
with glyburide compared with insulin. To estimate the association between drug class at
initiation and risk of change we calculated Risk Ratios (RR) and 95%CI.
All analyses were conducted using SAS v 9.3 (SAS Institute, Cary, NC). This study using
existing, de-identified data was determined to be exempt from further review by the Public
Health –Nursing Institutional Review Board, Office of Human Research Ethics at the
University of North Carolina at Chapel Hill.
RESULTS
Among women with a delivery code and who met our enrollment criteria (N=1,108,383),
122,064 had an eligible pregnancy complicated by GDM. Of these women, 10,778 (8.1%)
had a pharmacy claim for insulin (n=4,905) or glyburide (n=5,873) during the 150 days prior
to delivery. Among women treated pharmacologically the use of glyburide increased
monotonically from 7.4% in 2001 to 64.5% in 2011 becoming the more common treatment
since 2007 (Table 1). Comparing glyburide with insulin, the adjusted annual percent change
was higher between 2000–2007 (34.0% 95%CI 20.4,49.1) and reached a plateau after 2008
with an annual increase of 3.7% (95%CI 0.8,6.7). The increase was observed across all age
groups (Figure 2).
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Among women treated with glyburide or insulin, the mean age at baseline was 33 years (SD
4.9) compared to 32 (SD 5.2) years in those not treated pharmacologically. Among the
pharmacologically treated group, approximately half were prescribed glyburide (54.5%,
N=5,873). In bivariate analysis, glyburide use was less common than insulin use in the
Northeast (45.8% vs 54.2%) and more common in the South (56.4% vs 43.7%) and Midwest
(54.9% vs 45.1%) regions of the US (Table 1). There was a small variation between regions
in the proportion of women not treated pharmacologically, ranging from 88.1% to 93.8%.
The proportion of women with comorbidities was generally similar between treatment
groups, while those who were not treated pharmacologically had fewer co-morbid
conditions (Table 2).
In multivariate analyses comparing glyburide with insulin, those in the Northeast and
Midwest were less likely to be prescribed glyburide by 19% and 4%, respectively (PR 0.81
95%CI 0.76–0.87, p<0.0001; PR 0.96 95%CI 0.93–1.00, p<0.0001). Women with metabolic
syndrome (PR 0.71, 95%CI: 0.50– 0.99), hyperandrogenism (PR 0.77, 95%CI: 0.62– 0.97),
polycystic ovarian syndrome (PR 0.88, 95%CI: 0.78– 0.99), hypothyroidism (PR 0.89,
95%CI: 0.83– 0.96) or history of infertility treatment (PR 0.93, 95%CI: 0.86– 1.02) were
less likely to be treated with glyburide (Table 3). Among women with an ICD-9 diagnosis
code for obesity, there was no preference for one treatment over the other (PR 1.04, 95%CI:
0.98–1.10). Prior metformin use was not associated with initiation of glyburide (PR 1.01,
95%CI: 0.94– 1.09). The adjusted probability of being prescribed glyburide, varied by age
with a 5% decrease for every 10 year increase in age (PR 0.95, 95%CI: 0.91– 0.99) (Figure
2). When compared to bivariate analysis, we did not observe important changes in the point
estimates or confidence intervals after adjusting for covariates, except for obesity.
Among women initially treated with glyburide, 7.8% (N=461) received an additional
medication or switched to a different drug class. The most common drug classes were
insulin (N=387, 6.6%) or metformin (N=74, 1.3%). Among those initiating insulin, 1.1%
(n=54) had a change in treatment prior to delivery. In this group, 0.8% (n=37) subsequently
started glyburide and 0.3% (n=16) metformin. Women initiating glyburide were 8.1 times
more likely to have a change in treatment before delivery (RR 8.1, 95%CI: 6.0–10.8).
DISCUSSION
We found a marked increase in the use of glyburide for the treatment of GDM in a
commercially-insured United States cohort from 2000 to 2011 with a corresponding
decrease in insulin use. This trend was coincident with the publication of results from
randomized clinical trials (9–11) and observational studies (12–14, 20). Our results support
findings from recent studies showing widespread use of glyburide despite lack of conclusive
clinical evidence being available (3, 21). This trend need to be interpreted in the light of
changes in GDM diagnosis and initiation of pharmacotherapy in this population over time.
Among the comorbidities of interest for which we had data, we did not find strong
predictors of glyburide initiation. Women with infertility, polycystic ovarian syndrome and
hyperandrogenism were more likely to be treated with insulin as were those with
hypothyroidism or metabolic syndrome. Women with an obesity ICD-9-CM were equally
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likely to be prescribed with glyburide or insulin. Because insulin resistance is increased in
all these conditions, the degree of perceived insulin resistance could be an additional driver
of initial choice of treatment for GDM.
Few studies have reported on changes in treatment (switching or augmenting) after initiation
of medication. The majority focused on failure of glyburide (22–25). Less is known about
failure after initiation on insulin therapy, where only one trial (Langer 2000, N=24/203) and
one observational study (Gilson 2002, N=3/11) have reported frequencies between 12–27%.
Although treatment failure could explain changes in treatment, tolerance or preference could
also have a role. Our findings are consistent with previous literature where changes in
treatment are more common in women initiating glyburide.
Little is known about the role of age on the preference to initiate treatment with oral agents
among women with GDM. Our results provide evidence that age is one of the factors
associated with choice of therapy. This was most evident in recent years after the
dissemination of glyburide use (Figure 2). This may reflect more severe glucose intolerance
in older women as there is some evidence that GDM severity increases with age. These
findings are also consistent with studies showing that maternal age is a risk factor for failing
to achieve glucose control with glyburide (23)
Due to the nature of healthcare claims data, we could not consider the influence of glucose
tolerance test results, gestational age, biometrics (weight or height) or race-ethnicity on the
choice of therapy. We believe our definition of GDM in combination with the exclusion of
women who had early pharmacy claims for the drugs of interest yields a cohort of ‘true’
gestational diabetics. This approach was validated by Andrade et al who reported a positive
predictive value of 85% (95%CI: 71–94%) (26). Also, we were limited to the ascertainment
of obesity through the use of ICD-9-CM diagnosis codes. This was also validated by
Andrade et al who reported a high positive predictive value (92%, 95%CI: 90– 94) but low
sensitivity (33%) (26). While this suggests that there is considerable under-reporting of
obesity, women with the code are likely obese. Though misclassification is likely not
differential between the drug classes of interest, it could bias results towards the null and we
therefore cannot rule out the possibility of an effect of obesity on choice of treatment.
Because our population has employer-provided insurance, results from this study may not be
generalizable to those covered by Medicaid or the uninsured. In a recent study by Albrecht
et al, it was estimated that 61.4% of women with GDM would be privately insured.
Therefore our results are reflective of patterns of care among a large, nationwide
population(27).
Strengths of the study include sample size, ascertainment, and timing of medication use
based on dispensed prescriptions. Our study likely includes women with different degrees of
severity and is reflective of the full spectrum of patients treated in a variety of clinical
settings. By restricting our cohort to women who were continuously enrolled in the year
prior to delivery we assured that use of healthcare and pharmacy services would be
observable throughout pregnancy. Therefore medication use in our study is based on
pharmacy claims of dispensed drugs, which allowed us to identify the earliest prescription in
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pregnancy. By using pharmacy claims, we likely have better ascertainment of initiation of
treatment during pregnancy compared to self-report.
Dissemination of glyburide for the pharmacological treatment of GDM has been rapid and
our findings indicate that since 2007 it has become the more common choice, particularly
among younger, non-insulin resistant women. Due to its uptake, robust evaluation of
glyburide’s relative effectiveness is warranted to inform treatment decisions for women with
gestational diabetes.
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Figure 1. Identification of eligible pregnancies in cohort
After identifying date of earliest claim with a delivery code (Delivery Date) the pregnancy
episode was defined as occurring 365 days before delivery (Fig 1A). For women with two
pregnancies within a 12 month period, we identified the delivery dates for the first (Delivery
Date 1) and second (Delivery Date 2) pregnancies. To avoid including diagnosis codes from
the postpartum period of the first pregnancy, the pregnancy episode of the second pregnancy
only started 45 days after Delivery Date 1 (Fig 1B).
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Figure 2. Trends in glyburide prescribing, by age group
Proportions were estimated from multivariable Binomial regression analyses, adjusted for all
maternal comorbidities and prior metformin use. Reference line is threshold above which
treatment with glyburide exceeded 50% (χ2 test for linear trend for age p=0.02).
Castillo et al. Page 10











































Castillo et al. Page 11
Table 1
Distribution of Women Treated With Glyburide (n=5,873) Among Women Treated With Glyburide or Insulin,




 2001 7.4 68
 2002 13.5 155
 2003 22.7 361
 2004 33.1 631
 2005 41.1 869
 2006 48.4 881
 2007 56.4 1,090
 2008 59.4 1,278
 2009 60.8 1,966
 2010 62.3 1,807
 2011 64.5 1,672
Region
 Northeast 45.8 1,305
 Northcentral 54.9 2,965
 South 56.3 4,283
 West 55.3 2,152
 Unknown 60.3 73
*
Row percentages.
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